Friday, August 13, 2021 1:05:31 AM
Very excited for September 9th…Gene therspy research day is just 4 weeks away,
Recent DTIL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 11:30:35 AM
- Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 • Business Wire • 05/27/2026 06:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 09:20:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:31:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:31:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:30:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:30:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:30:18 AM
- Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 • Business Wire • 05/21/2026 11:01:00 AM
- Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting • Business Wire • 05/14/2026 11:01:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 11:20:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:19:27 AM
- Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update • Business Wire • 05/05/2026 11:01:00 AM
- Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 • Business Wire • 04/30/2026 11:01:00 AM
- Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study • Business Wire • 04/29/2026 11:01:00 AM
- Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting • Business Wire • 04/28/2026 11:01:00 AM
- Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/24/2026 11:01:00 AM
- Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 • Business Wire • 04/22/2026 11:01:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/15/2026 01:46:19 PM
- Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries • Business Wire • 04/15/2026 11:01:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/08/2026 11:01:42 AM
- Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference • Business Wire • 04/08/2026 11:01:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/08/2026 11:00:28 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/27/2026 08:05:50 PM
